Jordana Joy

An overview of the top 10 stories from Optometry Times in 2025.

Of the 1000 patients with dry eye symptoms surveyed, 80% stated that “they would try a science-backed eye drop that mimics natural tears and restores tear-film balance."

Researchers analyze the DREAM study, revealing lid margin collarettes in dry eye patients and their surprising lack of progression over time.

The trial met both its primary efficacy and key secondary endpoints.

Vizz is the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults

K8 was found to reduce geographic atrophy lesion area growth by more than 50% in its first human clinical trial of the drug.

Wavelight plus was first launched in China, with several European and Asia-Pacific markets following suit

The study will be evaluating the safety, tolerability, and efficacy of QLS-111 in adult patients with normal tension glaucoma.

The solution was approved by the US Food and Drug Administration in late May 2025.

A recent study reveals that many Americans neglect eye care due to cost and urgency misconceptions, despite the significant impact on daily life.

The law will work to remove outdated restrictions on medications and allow some in-office procedures and will take effect in August.

Alcon’s Voyager is a fully automated, noncontact treatment approach that delivers 120 laser pulses through the limbus of the trabecular meshwork.

New tariffs threaten the optical industry, prompting urgent reevaluation of sourcing strategies and pricing as deadlines approach.

Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.

The report divides the research into 7 categories: sex, gender, and hormones; epidemiology; pathophysiology; tear film; pain and sensation; iatrogenic; and clinical trial design.

Patients in Ontario expose illegal user fees for cataract surgeries in private clinics, urging government action to uphold the Canada Health Act.

ZinserLab will focus on accelerating the development of imaging technologies in eye care.

EssilorLuxottica and MidEuropa recently entered into an agreement that will allow EssilorLuxottica to acquire Optegra, building upon its med-tech strategy.

Lamivudine could provide an oral option to more effectively treat DME at a lower cost to patients

The preservative-free, contact lens–friendly drops have been formulated to provide hydration and comfort for dry eyes in a multidose bottle.

A recent US Court of International Trade decision was made on May 28 to permanently prohibit all tariffs imposed by President Donald Trump under the International Emergency Economic Powers Act.

Lori Wright, JD, sat down to talk about a discussion at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.